The cantons of Zug and Solothurn in the Greater Zurich Area are ideal locations for Biogen’s international headquarters due to the favorable environment it provides for businesses and employees.

One of the pioneers in biotechnology, Biogen today has the leading portfolio of medicines to treat multiple sclerosis (MS) and is at the forefront of research into new medicines for chronic conditions, including neurodegenerative disease, rare genetic disorders, and autoimmune diseases. Led by world-class research and development, Biogen uses novel science and leading-edge technologies to create, commercialize, and manufacture transformative therapies for patients with few or no treatment options. Biogen's global organization of more than 7,000 employees, including more than 1200 across 20 affiliates in Europe, and current and future manufacturing facilities in the US, European Union and Switzerland, is committed to a single mission: making a meaningful difference in the lives of patients suffering from devastating medical conditions.

For nearly two decades Biogen has led in the research and development of new therapies to treat MS, including the most prescribed oral treatment in the world. Now Biogen's research is driving revolutionary new MS treatments with the goal of reversing or even repairing damage caused by the disease. We are now applying our neurological expertise to solve some of most challenging and complex diseases of the brain, including Alzheimer’s disease, Parkinson’s disease, and ALS. As Biogen enters a transformative period in neurology, it is driving a deeper understanding of disease biology and developing life-changing treatments for the millions of people suffering from these conditions.

The international headquarters was established in Switzerland in 2004 and has grown to more than 400 employees. Zug is also home to Biogen’s Swiss affiliate, which was established in 2011, currently employing more than 30 people. The Company has also established its new biosimilars business unit in Zug. Biogen is currently investing CHF 1 billion into a next-generation manufacturing facility and is creating up to 400 new job in Luterbach near Solothurn.

The cantons of Zug and Solothurn are ideal locations for Biogen’s international headquarters due to the favorable environment it provides for businesses and employees. With an amicable setting, a stable economy and an efficient municipality, it is highly attractive for a diverse workforce.

Biogen is committed to being a responsible corporate citizen and regularly gives back to the communities in which it operates. Through the Company’s annual global day of service, called Care Deeply Day, employees volunteer for various projects throughout the region, many of which they return to year after year.  Also, in keeping with Biogen’s commitment to inspiring young people to consider innovative careers in science, the international headquarters has developed and cultivated long-standing relationships with some of the premier STEM (science, technology, education and math) programs in Switzerland including Swiss Science Center Technorama, KinderUniversität Zurich, and Swiss Youth in Science.


Biogen Logo


Biogen is where science meets humanity. With its rich history in neuroscience and its position at the heart of Europe, Switzerland is the ideal hub for us to bring our life-changing treatments in MS, SMA and other neurological diseases to people in more than 60 countries around the world.
Johanna Friedl-Naderer President of Europe, Canada & Partner Markets
Johanna Friedl-Naderer - President of Europe, Canada & Partner Markets, Biogen

Contact us

Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center? Give us a call or drop us a line. 

+41 44 254 59 59